elevartherapeutics
-
HLB Aims for Three Cancer Drug Approval and Groundbreaking Tumor-Agnostic Therapy by 2025Big Tech 2025. 2. 6. 16:38
· With its liver cancer drug approval decision just a month away, HLB targets breakthroughs in oncology, including a pioneering FGFR2-targeted tumor-agnostic therapy. SEOUL, South Korea, February 6, 2025 (IT Times) - With its liver cancer drug approval decision just a month away, HLB targets breakthroughs in oncology, including a pioneering FGFR2-targeted tumor-agnostic therapy. With just a mont..
-
HLB Presents Promising Interim Results of Rivoceranib at ESMO 2024Big Tech 2024. 9. 20. 02:24
· HLB's rivoceranib combination therapies show potential for expanded indications. SEOUL, South Korea, September 19, 2024 (IT Times) - HLB, a leading biopharmaceutical company, today announced that its subsidiary Eleva Therapeutics and its partner, Jiangsu Hengrui Pharmaceuticals, presented 11 study results related to rivoceranib at the European Society for Medical Oncology (ESMO) Congress 2024 ..
-
ASCO 2024: HLB's Rivoceranib Plus Camrelizumab Attracts a Liver Cancer Experts카테고리 없음 2024. 6. 4. 11:14
· Liver cancer experts are impressed by the rivoceranib plus camrelizumab combination's efficacy, minimal side effects, and potential to improve patient quality of life. SEOUL, South Korea, June 4, 2024 (IT Times) - HLB, a leading biopharmaceutical company, is making waves at the American Society of Clinical Oncology (ASCO) annual meeting. For the third year in a row, HLB's US subsidiary, Elevar..
-
HLB Announces Liver Cancer Treatment Results at ASCOBig Tech 2024. 6. 3. 16:47
· HLB's US subsidiary Elevar Therapeutics announced the updated Phase 3 CARES-310 study for uHCC at ASCO 2024. SEOUL, South Korea, June 3, 2024 (IT Times) - HLB, a leading biopharmaceutical company, today announced that the updated Phase 3 CARES-310 study evaluating a novel combination therapy with rivoceranib in unresectable hepatocellular carcinoma (uHCC) was presented as a poster at the Ameri..